Targeting Nerve Growth Factor for Pain Management in Osteoarthritis-Clinical Efficacy and Safety.
- Author(s): Dietz, Brett W;
- Nakamura, Mary C;
- Bell, Matthew T;
- Lane, Nancy E
- et al.
Published Web Locationhttps://doi.org/10.1016/j.rdc.2020.12.003
Nerve growth factor (NGF) is a neurotrophin that mediates pain sensitization in pathologic states, including osteoarthritis. In clinical trials, antibodies to NGF reduce pain and improve physical function due to osteoarthritis of the knee or hip and have a long duration of action. Rapidly progressive osteoarthritis is a dose-dependent adverse event with these agents, and additional joint safety signals, such as subchondral insufficiency fractures and increased rates of total joint replacement, are reported. The effects on pain and potential mechanisms behind these joint events both are of considerable importance in the consideration of future use of anti-NGF therapies for osteoarthritis.